Literature DB >> 3476204

Phase II study of amsacrine and high-dose cytarabine for resistant acute myelogenous leukemia.

R W Decker, W G Ho, R E Champlin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3476204

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  4 in total

Review 1.  Treatment strategies in acute myeloid leukemia (AML). B. Second line treatment.

Authors:  W Hiddemann; T Büchner
Journal:  Blut       Date:  1990-03

2.  High-dose ara-C and etoposide in refractory or relapsing acute leukemia.

Authors:  M Freund; H Link; H Diedrich; S LeBlanc; H J Wilke; H Poliwoda
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

3.  Phase-II study of treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrine.

Authors:  U Jehn; V Heinemann
Journal:  Ann Hematol       Date:  1993-03       Impact factor: 3.673

4.  Five-day 4'-(9-acridinylamino)methanesulphon-m-anisidide and intermediate-dose cytosine arabinoside in high-risk relapsing or refractory acute myeloid leukemia.

Authors:  M Freund; S Giller; F Hinrichs; A Baars; J Meran; A Körfer; H Link; H Poliwoda
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.